Tumour endothelial cells acquire drug resistance in a tumour microenvironment

Kyoko Hida, Kosuke Akiyama, Noritaka Ohga, Nako Maishi, Yasuhiro Hida

Research output: Contribution to journalReview articlepeer-review

61 Citations (Scopus)

Abstract

Tumour growth is dependent on angiogenesis, and tumour blood vessels are recognized as an important target for cancer therapy. Tumour endothelial cells (TECs) are the main targets of anti-angiogenic therapy. Unlike the traditionally held view, some TECs may be genetically abnormal and might acquire drug resistance. Therefore, we investigated the drug resistance of TECs and the mechanism by which it is acquired. TECs show resistance to paclitaxel through greater mRNA expression of multidrug resistance 1, which encodes P-glycoprotein, as compared with normal endothelial cells. We found that high levels of vascular endothelial growth factor in tumour-conditioned medium may be responsible for upregulated P-glycoprotein expression. This is a novel mechanism for the acquisition of drug resistance by TECs in a tumour microenvironment. This review focuses on the possibility that TECs can acquire drug resistance.

Original languageEnglish
Pages (from-to)243-249
Number of pages7
JournalJournal of Biochemistry
Volume153
Issue number3
DOIs
Publication statusPublished - 03-2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology

Fingerprint

Dive into the research topics of 'Tumour endothelial cells acquire drug resistance in a tumour microenvironment'. Together they form a unique fingerprint.

Cite this